Sidonie Lambert-Niclot
Overview
Explore the profile of Sidonie Lambert-Niclot including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
68
Citations
1032
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Wirden M, Tombette F, Lambert-Niclot S, Chaix M, Marque-Juillet S, Bouvier-Alias M, et al.
J Int AIDS Soc
. 2025 Jan;
28(2):e26416.
PMID: 39875664
Introduction: Molecular surveillance is an important tool for detecting chains of transmission and controlling the HIV epidemic. This can also improve our knowledge of molecular and epidemiological factors for the...
2.
Wirden M, Abdi B, Lambert-Niclot S, Chaix M, De Monte A, Montes B, et al.
J Antimicrob Chemother
. 2025 Jan;
80(3):692-696.
PMID: 39786501
Background: The S147G mutation is associated with high-level resistance to the integrase strand transfer inhibitor (INSTI) elvitegravir. In several poorly documented cases, it was also selected in patients on dolutegravir....
3.
Abe E, Landman R, Assoumou L, Amat K, Lambert-Niclot S, Bellet J, et al.
J Antimicrob Chemother
. 2024 Apr;
79(6):1380-1384.
PMID: 38656448
Objectives: Charaterization of the plasma concentrations of antiretrovirals in a 4-days-a-week maintenance treatment strategy in the ANRS-170-QUATUOR study. Methods: Patients were randomized in two groups receiving triple therapy taken 4-days-ON...
4.
Valin N, Lambert-Niclot S, Torres E, Meynard J, Perillaud-Dubois C, Morand-Joubert L, et al.
Clin Infect Dis
. 2024 Mar;
79(1):196-197.
PMID: 38513236
A case of a male with human immunodeficiency virus with plasma genotyping detecting no resistance and a CRF02_AG subtype had a controlled HIV RNA on antiretroviral therapy since 2010. We...
5.
Giammarino F, De Salazar A, Malet I, Vinuela L, Fuentes A, Saladini F, et al.
J Infect Dis
. 2024 Jan;
229(6):1796-1802.
PMID: 38206187
Background: Limited data are available regarding the susceptibility of the reverse transcriptase V106 polymorphism to doravirine. Methods: Doravirine susceptibility was measured in site-directed mutants (SDMs) containing V106I, V106A, V106M, and...
6.
Devred I, Kayembe K, Valin N, Rougier H, Shinga B, Lambert-Niclot S, et al.
BMC Infect Dis
. 2023 Sep;
23(1):578.
PMID: 37667182
HIV post- exposure prophylaxis (PEP) is a prevention tool for individuals with a recent potential exposure to HIV. Doravirine has been available since 2019 in combination with tenofovir disoproxil fumarate...
7.
Lambert-Niclot S, Abdi B, Bellet J, Fofana D, De Truchis P, Amat K, et al.
J Antimicrob Chemother
. 2023 Apr;
78(6):1510-1521.
PMID: 37104815
Background: In a 4 days/week (4/7 days) maintenance strategy (ANRS-170 QUATUOR trial), the virological impact of an intermittent strategy was assessed by ultrasensitive virological analyses of reservoirs and resistance. Methods:...
8.
Fofana D, Diarra H, Guindo I, Savadogo M, dAlmeida M, Diallo F, et al.
Viruses
. 2023 Feb;
15(2).
PMID: 36851760
Integrase inhibitors (INIs) are a potent option for HIV treatment. Limited data exist on INI resistance in West Africa, particularly in children living with HIV/AIDS. We determined the prevalence of...
9.
Shinga Wembulua B, Valin N, Lambert-Niclot S, Nerozzi-Banfi E, Chiarabini T, Meynard J, et al.
J Acquir Immune Defic Syndr
. 2023 Feb;
92(3):e17-e18.
PMID: 36729654
No abstract available.
10.
De Salazar A, Vinuela L, Fuentes A, Teyssou E, Charpentier C, Lambert-Niclot S, et al.
Clin Infect Dis
. 2022 Dec;
76(9):1628-1635.
PMID: 36571282
Background: We evaluated the prevalence of transmitted drug resistance (TDR) to integrase strand-transfer inhibitors (INSTIs) and nucleoside/nucleotide reverse transcriptase inhibitors (NRTIs) and of clinically relevant resistance (CRR) in newly diagnosed...